Observational studyJournal of thrombosis and thrombolysis2025
Prediction of thrombotic events in patients with autoimmune hemolytic anemia: a multicenter retrospective observational study.
Observational study in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune hemolytic anemia (AIHA) is recognized to increase the risk of thrombotic events (TE), including venous thromboembolism (VTE) and arterial thromboembolism (ATE), but little is known about specific risk factors and characteristics.
methodsThis retrospective multicenter observational study, sought to assess TE incidence, identify associated thrombotic risk factors and assess the external validity of the Padua score in AIHA for predicting VTE.
resultsTE incidence during the study period was 25% (CI95%: 17-36), consisting of 19 VTE in 16 patients (18% [CI95%: 9-28]) and 11 ATE in 7 (8% [CI95%: 4-16]). A high number (≥ 5) of hemolysis attacks was associated with overall TE (OR 6.9 [CI95%: 1-82], p = 0.03). Univariate analysis confirmed splenectomy and VTE history as the strongest VTE-related risk factors (OR 7.5 [CI95%: 1-44], p = 0.009 and OR 3.8 [CI95%: 1-14], p = 0.04), whereas having primary warm AIHA was identified as a novel risk factor (3.1 [1-11] p = 0.05) which needs to be confirmed in further studies. ATE risk factors were age≥ 80 years at diagnosis (OR 8.9 [CI95%: 1-68] p = 0.02), and having ≥ 3 cardiovascular risk factors (OR 8.9 [CI95%: 1-70] p = 0.01). The area under the Receiver Operating Characteristic curve of the Padua score was 0.66.
conclusionsTE incidence is high in AIHA, especially when there are repeated hemolysis attacks and associated VTE and/or ATE-related risk factors, thus warranting the conduct of prospective clinical trials to allow for an improved TE risk stratification and to design adapted management for both VTE and ATE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.